top of page

Groups Feed

View groups and posts below.


This post is from a suggested group

PTA Balloon Catheters Devices Market — Enhancing Cardiovascular Interventions through Minimally Invasive Solutions

Market OverviewThe Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters Devices Market includes balloon catheters used in vascular interventions to dilate stenosed or occluded blood vessels. Applications include coronary artery disease, peripheral artery disease, and other cardiovascular procedures.


The market serves hospitals, cardiology clinics, interventional centers, and catheterization labs. Rising prevalence of cardiovascular diseases, minimally invasive procedures, and technological advancements drive market growth.

Market DriversDrivers include increasing cardiovascular disease prevalence, aging population, and rising demand for minimally invasive interventions. Technological innovations, such as drug-coated balloons, high-pressure balloons, and dual-lumen catheters, enhance procedural safety and efficacy. Insurance coverage for cardiovascular procedures and growing hospital infrastructure further support market expansion.

Market Trends and OpportunitiesTrends include combination therapies with stents, bioresorbable materials, precision angioplasty systems, and image-guided interventions. Opportunities exist in emerging markets, outpatient catheterization centers, and hospitals upgrading cardiovascular services. Training programs and clinician support improve procedural success rates.

ChallengesChallenges include high device costs,…

3 Views

This post is from a suggested group

12412412

123412

60 Views

This post is from a suggested group

The European Society of Medicine published NDR's opinion piece Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach. The editorial is support for our position that thymopentin in the form of FC-12738 can bring a major contribution to the ALS field because it is designed to regulate the cell danger response by natural innate immune pathways. It was Richards hope to bring such a treatment to those diagnosed with ALS. The human trial (in normal subjects) wrapped up with no issues. When the paperwork completes we will move into ALS patients. Richard would be pleased.


ree

This post is from a suggested group

May 28, 2024 · added a group cover image.
ree

This post is from a suggested group

In the great effort to bring treatments to ALS patients Richard funded a clinical trial for FC-12738. This molecule is novel (Richard and I called it TVALA)...the world has never seen it before! It engages the failing immune system and will (hopefully) RESET an ALS patient's ability to normalize neuroinflammation—slowing disease and allowing doctors to stack additional life-saving therapies as patients change over the course of their illness.


The down side...the world has never seen this molecule before! The ever cautious FDA wants us to dose some normal folk before we go after saving ALS patients. Richard's Study enrolls 2 people (one dosed and one not, they are called sentinels) and if no one is adversely affected, and they are still alive after 8 days, we can then dose 6 additional normal people (at the same dose). We are happily reporting no adverse events after 8 folk got 4 m…


ree

Meyer Odette
Meyer Odette
Aug 19, 2024

Last year, my 68-year-old partner was diagnosed with Lou Gehrig's disease also known as ALS. Speaking and swallowing were two of his challenges. His collapse was swift and catastrophic, and neither the riluzole nor the medical staff did much to aid him. He would not have survived if our primary care physician hadn't given him attentive care and attention, as the hospital center didn't provide any psychological support. His fall was abrupt and catastrophic. His hands and legs gave way to weakness in his arms. This year our family physician suggested using vinehealthcentre. com ALS/MND treatment, which my husband has been receiving for a few months now. I'm delighted to say that the treatment greatly reduced and reversed his symptoms of ALS, he no longer requires a feeding tube, sleeps soundly, works out frequently, and is now very active. In the hopes that it could be useful, I thought I would relate my husband's tale; in the end, you have to do what suits you the best.

This post is from a suggested group

This group is for those of you that donated to NDR. We wanted to create a space to let you know how we were spending your generous donations.

Sometimes we can't share things publicly, we have to wait until things are published to share to everyone. Alas, publication takes a year to see.

Our work moves quite quickly and we want to share the excitement as it happens. I used to do this daily with Richard and I miss those communications.

Before he stopped flying, Richard would buzz us in the lab in this plane— or hover his helicopter in our treetops! He'd always make a path across us when he returned home from a flight, low and full throttle. We miss that too!!


ree

This post is from a suggested group

Welcome to our group NDR Group! A space for us to connect and share with each other. Start by posting your thoughts, sharing media, or creating a poll.

bottom of page